Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KD-414 multicenter open-label safety and immunogenicity study in healthy Japanese adults
jRCT2071210081Completed
- Sponsor
- KM Biologics
- Start
- Oct 2021
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of KD-414 in coronavirus disease 2019 (COVID-19), sponsored by KM Biologics. Primary endpoints: Geometric mean neutralizing antibody titer after doses 2, 3, and 4, Overall adverse events through post-third vaccination test and 7 more. Started Oct 2021; status: completed.
02
Drugs
KD-414
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2071210081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210081.